United States Adults Meeting 2010 American College of Rheumatology Criteria for Treatment and Prevention of Glucocorticoid-Induced Osteoporosis

EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases

(2013) N Duru et al.   ANNALS OF THE RHEUMATIC DISEASES

Recent recommendations on steroid-induced osteoporosis: More targeted, but more complicated

(2013) C. L. DEAL   CLEVELAND CLINIC JOURNAL OF MEDICINE

The Disconnect Between Better Quality of Glucocorticoid-induced Osteoporosis Preventive Care and Better Outcomes: A Population-based Cohort Study

(2013) S. R. Majumdar et al.   JOURNAL OF RHEUMATOLOGY

Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013

(2013) J. Compston et al.   MATURITAS

Influence of recency and duration of glucocorticoid use on bone mineral density and risk of fractures: population-based cohort study

(2013) S. R. Majumdar et al.   OSTEOPOROSIS INTERNATIONAL

Population-Based Trends in Osteoporosis Management after New Initiations of Long-Term Systemic Glucocorticoids (1998–2008)

(2012) S. R. Majumdar et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis

(2012) S. Lekamwasam et al.   OSTEOPOROSIS INTERNATIONAL

Prevalence of oral glucocorticoid usage in the United States: A general population perspective

(2012) Robert A. Overman et al.   ARTHRITIS CARE & RESEARCH

Diretrizes para prevenção e tratamento da osteoporose induzida por glicocorticoide

(2012) Rosa Maria Rodrigues Pereira et al.   Revista Brasileira De Reumatologia

Management and Treatment of Osteoporosis in Patients Receiving Long-term Glucocorticoid Treatment: Current Status of Adherence to Clinical Guidelines and Related Factors

(2011) Daijun Kirigaya et al.   INTERNAL MEDICINE

Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis

(2011) Karen E Hansen et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Official Positions for FRAX® Clinical Regarding Glucocorticoids: The Impact of the Use of Glucocorticoids on the Estimate by FRAX® of the 10 Year Risk of Fracture

(2011) Edward S. Leib et al.   JOURNAL OF CLINICAL DENSITOMETRY

Lumbar spine bone mineral density in US adults: demographic patterns and relationship with femur neck skeletal status

(2011) A. C. Looker et al.   OSTEOPOROSIS INTERNATIONAL

The potential impact of the National Osteoporosis Foundation guidance on treatment eligibility in the USA: an update in NHANES 2005–2008

(2011) B. Dawson-Hughes et al.   OSTEOPOROSIS INTERNATIONAL

Guidance for the adjustment of FRAX according to the dose of glucocorticoids

(2011) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL

Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years

(2011) L. Fardet et al.   RHEUMATOLOGY

Management of glucocorticoid-induced osteoporosis

(2010) Juliet Compston   Nature Reviews Rheumatology

American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis

(2010) Jennifer M. Grossman et al.   ARTHRITIS CARE & RESEARCH

Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial

(2009) Kenneth G. Saag et al.   ARTHRITIS AND RHEUMATISM

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

(2009) David M Reid et al.   LANCET

A Revised Clinician’s Guide to the Prevention and Treatment of Osteoporosis

(2008) Bess Dawson-Hughes   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

FRAX™ and the assessment of fracture probability in men and women from the UK

(2008) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL